The earnings beat on operating loss and multiple pipeline catalysts (LP-300 data, LP-184 regulatory clearances, OMAI spin-off) are positive signals, but the $7.4M cash position provides limited runway through mid-Q1 2027, making additional capital raises likely. Monitor the mid-September OMAI investor call for commercial traction and any partnership or licensing deal for LP-300 or LP-184.
Price Chart
Executive Summary
Lantern Pharma reported Q2 2026 operating loss of $3.5M ($0.28/share), beating consensus of $0.38/share by 26.3%, driven by a 42% reduction in R&D spend. Net loss widened to $7.1M ($0.57/share) due to non-cash warrant expense. Key pipeline catalysts include deepened LP-300 PFS data in EGFR L858R, EMA clearance for LP-184 in bladder cancer, and establishment of Open Medicine AI as a separate entity. Cash position $7.4M extends runway into mid-Q1 2027.
Key Financial Metrics
Key Facts
- Q2 2026 operating loss $3.5M, down 25% YoY from $4.7M
- EPS -$0.28 vs consensus -$0.38 (26.3% beat)
- Net loss $7.1M ($0.57/share) vs $4.3M ($0.40) YoY, driven by $3.6M non-cash warrant expense
- Cash, cash equivalents and marketable securities $7.4M as of June 30, 2026
- LP-300 HARMONIC trial: median PFS 8.9 months in EGFR L858R patients completing 6 cycles (n=9), HR 0.37
- EMA cleared Phase 1b/2 trial of LP-184 (zirdafulven) in biomarker-selected bladder cancer
- FDA cleared Phase 1b/2 LP-184 trial in TNBC with homologous recombination deficiency
- USPTO Notice of Allowance for three-gene patient-selection signature for LP-184
- Open Medicine AI (OMAI) established as separate company with executed commercial licensing agreements
Financial Impact
Operating loss beat by 26% YoY improvement; net loss worse due to warrant accounting; cash burn rate ~$2.7M/quarter
Risk Factors
- Cash runway only until mid-Q1 2027; requires additional financing
- LP-300 data is exploratory from small patient cohorts; may not replicate in larger trials
- No approved products or revenue; clinical-stage risk across all pipeline assets
- Warrant expense from May 2026 offering creates GAAP net loss volatility
- OMAI spin-off may not achieve expected valuation or funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-037979 |
| Document: form8-k.htm | 0001493152-26-037979 |
| Document: 0001493152-26-037979-index-headers.html | 0001493152-26-037979 |
| Document: 0001493152-26-037979-index.html | 0001493152-26-037979 |
| Document: 0001493152-26-037979.txt | 0001493152-26-037979 |
| 8-K Data (Synthetic) | 0001493152-26-037979 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $0.6564 | awaiting T+60 | — | $0.6240 (+4.94%) |
Oct 13, 2026 13d ago | SC 13G/A | $0.7107 | awaiting T+60 | — | $0.6240 (−12.20%) |
Oct 1, 2026 25d ago | 8-K | $0.8601 | awaiting T+60 | — | $0.6240 (+27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.00 | awaiting T+60 | — | $0.6240 (+37.60%) |
Sep 30, 2026 26d ago | 424B5 | $1.01 | awaiting T+60 | — | $0.6240 (+38.22%) |
Sep 23, 2026 4w ago | 8-K | $1.21 | awaiting T+60 | — | $0.6240 (−48.43%) |
Sep 23, 2026 4w ago | 8-K | $1.39 | awaiting T+60 | — | $0.6240 (−55.11%) |
Aug 14, 2026 10w ago | 8-K | $2.65 | awaiting T+60 | — | $0.6240 (−76.45%) |
Jun 22, 2026 18w ago | EFFECT | $3.88 $1.70 | ▲ +56.19% | ▲ +57.93% | $0.6240 (+83.92%) |
May 15, 2026 23w ago | 8-K | $3.00 $2.66 | ▼ −11.33% | ▼ −16.18% | $0.6240 (−79.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers